At the news
? MIXEDIMPACT 5/10 PRESS-RELEASE filed Mar 31, 2026 at 07:30 ET
MiNK Therapeutics reported financial results for Q4 and full year 2025, highlighting a net loss increase to $12.5M but improved cash position of $13.4M, supported by non-dilutive funding and a recent $3M raise. The company emphasized pipeline progress, including upcoming Phase 2 trials in ARDS and GVHD, with multiple clinical catalysts expected in 2026.
- Net loss for FY 2025 was $12.5 million, up from $10.8 million in 2024.
- Cash and cash equivalents totaled $13.36 million as of December 31, 2025, up from $4.58 million in 2024.
- Raised additional $3.0 million post-year-end via at-the-market offering, extending cash runway into 2026.
- Phase 2 trial for agenT-797 in ARDS to initiate in 1H 2026, with early data expected by year-end.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access